NCT01861340

Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma

Pilot Study of Lenalidomide and Dexamethasone in Combination With MEDI-551 in Previously Untreated Multiple Myeloma.

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

This research study is being done to see if combining the investigational chemotherapy drug, MEDI-551 with the known anti-myeloma drugs, Lenalidomide and Dexamethasone will reduce your myeloma cancer stem cells.

Detailed description

To explore the effect of Lenalidomide, dexamethasone and Medi-551 on multiple myeloma cancer stem cells (CSCs). Myeloma CSCs will be assessed by a clonogenic assay from the bone marrow and flow cytometry from peripheral blood.

Conditions

• Myeloma

Interventions

Type	Name	Description
DRUG	Lenalidomide, Dexamethasone, and MEDI-551	Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.

Timeline

• Start date: 2014-05-01
• Primary completion: 2016-04-01
• Completion: 2016-07-01
• First posted: 2013-05-23
• Last updated: 2018-09-10

Locations

1 site across 1 country: United States